MedDataX Logo

Management of the Idiopathic Overactive Bladder With Botulinum Toxin: Systematic Review

NCT ID: NCT01750645

Last Updated: 2012-12-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Study Classification

OBSERVATIONAL

Study Start Date

2012-07-31

Study Completion Date

2013-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Overactive bladder is defined as a syndrome composed of urgency, increased urinary frequency, and sometimes urinary incontinence; its etiology may be characterized as neurogenic or non-neurogenic (i.e., idiopathic). This illness has a great impact in quality of life and one of the available treatments is the injection of Botulinum Toxin. This study aims to review the efficacy and safety of type-A Botulinum Toxin in the management of Idiopathic Overactive Bladder. A systematic search was performed in MEDLINE, EMBASE, CENTRAL and LILACS, and the controlled randomized clinical trials were chosen to review with the CONSORT criteria by independent reviewers. Outcomes analyzed were the efficacy of the intervention for relieving the symptoms (urgency, frequency and urgency incontinence), adverse events to treatment, change in quality of life and urodynamic measures.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Urinary Bladder, Overactive

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention Group

Intradetrusor Injection of Type-A Botulinum Toxin

Intervention Type DRUG

Control Group

Other interventions analyzed according to protocol

Intervention Type OTHER

* Placebo
* Different dosage of Type-A Botulinum Toxin injected
* Anticholinergic drugs

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intradetrusor Injection of Type-A Botulinum Toxin

Intervention Type DRUG

Other interventions analyzed according to protocol

* Placebo
* Different dosage of Type-A Botulinum Toxin injected
* Anticholinergic drugs

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Controlled randomized clinical trials
* Adult patients diagnosed with idiopathic overactive bladder
* Language of the study: english

Exclusion Criteria

* Diagnosis of neurogenic overactive bladder
* Patients under 18 years old
* Use of Type-B Botulinum Toxin as the intervention
* Other types of studies
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Clínica Infantil Colsubsidio

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hugo Enrique López, MD

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hugo E López, MD

Role: PRINCIPAL_INVESTIGATOR

Clínica Infantil Colsubsidio

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clínica Infantil Colsubsidio

Bogotá DC, Bogotá DC, Colombia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Colombia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

COLS-201207

Identifier Type: -

Identifier Source: org_study_id